Overview

We have spent over fifteen years specializing in neuroimaging and the efficient application of imaging (PET and MRI) biomarkers in drug development and clinical research for neurodegenerative and neuropsychiatric disorders. Invicro has extensive expertise in coordinating worldwide multi-center imaging studies, and providing management and oversight of radiotracer supply globally for both commercial and non-commercially available agents. Our neurology experience includes:

 

  • Managed 300+ clinical nuclear medicine trials
  • Conducted >50 large, multi-center trials using PET and MRI modalities
  • Two clinical imaging centers supporting over 90 novel neuro imaging agents
  • Redefining imaging analytic techniques
Capabilities

Invicro’s neurology capabilities include the execution of large-scale clinical trials for diagnosis, progression, and disease monitoring trials that emphasize quantitative imaging outcome measures. With our integrated neuroimaging capabilities and services that span the needs of your trial, Invicro offers:

 

  • Clinical imaging center coordination and project management programs
  • Imaging center evaluation, selection, setup, training and management
  • Core imaging lab services to monitor and manage dose supply and distribution, receive, and quality control imaging data
  • Rapid analyses for study eligibility
  • Quantitative analysis for monitoring drug effect
  • Image data management and regulatory compliance services
  • Cryofluorescence Tomography (CFT)
  • Autoradiography (ARG)
Modalities
  • PET
  • SPECT
  • MRI
  • CT
  • Additional novel modalities include: Resting state fMRI, phMRI, MRS, DCE-MRI, ALS and Dynamic X-Ray
Experience

Invicro has industry leading operational oversight and extensive experience with early phase, single-site and late phase, multi-center trials. This enables us to provide sponsors with unparalleled support and guidance to ensure successful study execution.

 

  • Managed 300+ clinical nuclear medicine trials
    • >150 Alzheimer and Parkinson studies
    • >30,000 Alzheimer’s and >3,700 Parkinson’s subjects imaged
  • Conducted >50 large, multi-center trials using PET and MRI modalities
    • Have qualified 1500+ imaging centers worldwide
  • Have 2 clinical imaging centers that support over 90 novel neuro imaging agents
  • Redefining imaging analytic techniques
    • Amyloid and Tau IQ analytics
    • SUV generation
    • Centiloid Mapping
Studies & Publications

Coming soon!